Study of Myocardial Function by Speckle Tracking After Cancer Treatment With Anthracyclines in Childhood

Myocardial Function Clinical Trial

— SPECKLEANTHRA  

Official title:

Study of Myocardial Function by Speckle Tracking After Cancer Treatment With Anthracyclines in Childhood

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02893787
• Other study ID #: 9396
• Status: Completed
• Start date: January 2015
• Est. completion date: January 2017

Study information

• Verified date: February 2022
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The main goal of this study is to compare the values of echocardiographic parameters obtained by Speckle Traking analysis on myocardial function among patients under 18 years treated with anthracyclines in childhood, with healthy age and sex mached volunteers.

Description:

Anthracyclines are major drugs in the treatment of childhood cancers. The main factor limiting their use is the occurrence of delayed cardiac toxicity, irreversible, in an dilated form of potentially fatal cardiomyopathy. This delayed cardiotoxicity secondary to the destruction of myocardial cells is histologically proven after administration of the first dose of anthracyclines. The main known risks factors for delayed cardiotoxicity are: the cumulative dose of anthracyclines, young age at the time of administration, and association with mediastinal radiotherapy. All pediatric protocols with anthracyclines therefore provide a prolonged cardiac monitoring. However, there are no validated predictive early markers of progression to cardiomyopathy: i) the standard echocardiography, routine surveillance method does not detect subclinical myocardial injury, ii) the predictive value of biomarkers (ultrasensitive troponin, NT-pro-BNP) is controversial because of conflicting results. Among the echocardiographic innovative techniques, myocardial strain imaging by speckle tracking echocardiography analyses via a software myocardial displacement of natural acoustic markers, and enables rapid evaluation, precise and objective of the segmental and global myocardial function, expressed as a percentage (strain) and speed of myocardial deformation (strain rate) by reference segment and by reference dimension (longitudinal, radial, circumferential). Only four recent studies analysing the myocardic function in ST of the patients treated with anthracyclines in childhood (Yiu-fai, Cheung, Yu W, Poterucha) find unmatched and/or incomplete results, on a limited number of patients, but suggest the existence of alterations of the left ventricle the strain before the appearance of deteriorations of the fraction of ejection of the left ventricle (LVEF). None of these studies studied the strain of the right ventricle and none compared the data of the strain with the cardiac biomarkers. Primary objective Compare the values of echocardiographic parameters obtained by the technique of ST on myocardial function among patients under 18 years treated with anthracyclines in childhood, with healthy age and sex mached volunteers. Secondary objectives To compare conventional echocardiographic parameters and ST them in terms of deviation from the norm To assess the impact of known risk factors for cardiotoxicity with anthracyclines (cumulative dose, young age at administration, female association with mediastinal radiotherapy) on ultrasound parameters obtained by the technique of ST. To evaluate the association between biomarkers for cardiotoxicity (ultrasensitive troponin and NT-pro-BNP) and echocardiographic parameters obtained by the technique of ST. To correlate indices of Speckle Tracking methods to classical sonographic data

Recruitment information / eligibility

• Status: Completed
• Enrollment: 196
• Est. completion date: January 2017
• Est. primary completion date: July 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion criteria:

• Patient treated between 0 and 18 with anthracyclines for malignancy
• Discontinuation of treatment with chemotherapy for over 1 year
• Patient in remission of his malignancy
• Lack of heart or lung disease associated
• No opposition patient and legal guardian
• Patient younger than 18 at the time of the study.

Exclusion criteria:

• Progressive malignant pathology.
• Cardiac, lung or muscle chronic diseases, etiology other than secondary to treatment with anthracyclines
• Refusal to participate in the study
• Poor echogenicity

Related Conditions & MeSH terms

• Chilhood Cancers
• Echographic Parameters Obtaind by Speckle Tracking
• Myocardial Function

Intervention

Other:
• Speckle Tracking Echocardiography
Echocardiography analyses

Locations

Country	Name	City	State
France	University Hospital of Montpellier	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

References & Publications (1)

Amedro P, Vincenti M, Abassi H, Lanot N, De La Villeon G, Guillaumont S, Gamon L, Mura T, Lopez-Perrin K, Haouy S, Sirvent A, Cazorla O, Vergely L, Lacampagne A, Avesani M, Sirvent N, Saumet L. Use of speckle tracking echocardiography to detect late anthr — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Echocardiographic parameters obtained by Speckle Tracking		Immediat